Turn Therapeutics (TTRX) Non-Current Assets (2024 - 2026)

Turn Therapeutics (TTRX) posted quarterly Non-Current Assets of $7.2 million for Q1 2026, up 3.24% quarter-over-quarter from $7.0 million in Q4 2025.

Turn Therapeutics (TTRX) Non-Current Assets (2024 - 2026) Analysis & Trends

Turn Therapeutics' Non-Current Assets history runs 3 years deep, the most recent figure standing at $7.2 million for Q1 2026.

In Q1 2026, Non-Current Assets changed N/A year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $7.0 million, up 632.5% from the prior year.
Non-Current Assets for Q1 2026 stood at $7.2 million, up from $7.0 million in the prior quarter.
The five-year high for Non-Current Assets was $7.2 million in Q1 2026, with the low at $950965.0 in Q4 2024.
The 3-year median for Non-Current Assets is $4.0 million (2025), against an average of $4.0 million.
Peak annual rise in Non-Current Assets reached 632.5% in 2025, while the deepest fall reached 632.5% in 2025.
Turn Therapeutics' Non-Current Assets stood at $950965.0 in 2024, then soared by 632.5% to $7.0 million in 2025, then increased by 3.24% to $7.2 million in 2026.
Business Quant data shows TTRX's Non-Current Assets at $7.2 million in Q1 2026, $7.0 million in Q4 2025, and $1.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.96 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	294.93 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.96 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3.76 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	18.06 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	938.60 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	468.65 Mn
10	Turn Therapeutics	285.07 Mn	285.07 Mn	-	6.53 Mn

Download Data